Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (12393)	12/5/1999 10:19:00 AM
From: aknahow	Respond to of 17367

The entire article was available. One of the things it said was that BPI21 works as well as the whole molecule. Also discussed how LBP and BPI21 worked together. This is a 1998 article. The patent that covers BPI25 had a similar theme. The importance of the article to me included the authors, Weiss and Ellsbach and what I as a lay-person take as confirmation that the whole BPI/LBP area covers a much broader range of applications than many Yahoo posters think. The references alone provide an indication of the extent of research being done on BPI and LBP. If XOMA ever gets funded by a Mycoprex and or a Neuprex deal as well as sales of Neuprex for Meningococcemia I think we will have an interesting time as the whole world begins to talk about the actual and potential benefits of BPI/LBP and how great the management of XOMA was to stick to its guns and not sell out for a pitance. What do you think the article said?

To: Bluegreen who wrote (12393)	12/5/1999 10:36:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

Bluegreen, I admit I get irritated with Yahoo posters that try to make XOMA look like a company that has always failed. Even Cacaito, overcomes his bitterness, to admit that XOMA has done important things a a MAB company. Each time I read about Rituxan I remember that XOMA played a key part. I applauded their sale of the royalties so can complain about that decision. But if people think that those in other companies are not aware of the contribution made by XOMA, they are wrong. Genentechs 1995 annual report carried no fewer than 8 favorable references to XOMA. Rituxan is one of the few MABs to enjoy such great success. <<<<<<"The diverse data presented at ASH will provide insights into the safety and broad potential applicability of Rituxan to target various CD20-positive B-cell malignant and non-malignant hematological disorders," said Gwen Fyfe, M.D., Genentech's senior director of Oncology. ">>>>>>>>> From a Dec. 4 DNA press release.